1. Generics Bulletin
  2. >>Business

Nippon Chemiphar’s Generics Business Continues To Recover

As Japanese Company Sees 2.4% Growth In Generics Segment

 
• By Akriti Seth

Nippon Chemiphar’s generics business continues to recover after two good quarters back-to-back. The Japanese company took time to stabilize after setbacks due to the adverse effect of National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic. 

recovery
Nippon Chemiphar is on its road to recovery with single-digit growth in generics segment • Source: Alamy

Japan’s Nippon Chemiphar Co., Ltd. has reported a slight increase in its generics sales to ¥12.58bn ($110m) in the firm’s financial second quarter ended 30 September 2021, compared to the ¥12.28bn reported in the prior-year period. The company clocked in overall pharmaceutical sales of ¥15.12bn in Q2 FY21, compared to ¥14.57bn in the corresponding quarter of the previous year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.